請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/51721
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 胡務亮 | |
dc.contributor.author | Wei-Chih Chen | en |
dc.contributor.author | 陳偉智 | zh_TW |
dc.date.accessioned | 2021-06-15T13:46:17Z | - |
dc.date.available | 2016-02-24 | |
dc.date.copyright | 2016-02-24 | |
dc.date.issued | 2015 | |
dc.date.submitted | 2015-11-26 | |
dc.identifier.citation | Rahimov, F. and L. M. Kunkel (2013). 'Cellular and molecular mechanisms underlying muscular dystrophy.' The cell biology of disease 201(4): 499-510.
Dalkilic, I. (2003). 'Muscular dystrophies: genes to pathogenesis.' Current Opinion in Genetics & Development 13(3): 231–238. Bushby, K. (2004). 'Recent advances in pediatric muscular dystrophies.' Current Pediatrics 14(3): 214-222. Bushby, K. (2010). 'Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management.' The lancet neurology 9(1): 77-93. Potnis-Lele, M. (2012). 'Genetic etiology and Diagnostic strategies for Duchenne and Becker Muscular Dystrophy: A 2012 update.' Indian Journal of Basic & Applied Medical Research 2(5): 357-369. Ciafaloni, E. (2009). 'Delayed Diagnosis in Duchenne Muscular Dystrophy: Data from the Muscular Dystrophy Surveillance, Tracking, and Research Network.' The Journal of Pediatrics 155(3): 380-385. Quinlivan (2014). 'Early diagnosis of Duchenne muscular dystrophy is essential to improve long term outcomes.' Arch Dis Child 99(12): 1061. Takeshima, Y. (2010). 'Mutation spectrum of the dystrophin gene in 442 Duchenne/Becker muscular dystrophy cases from one Japanese referral center.' Journal of Human Genetics 55: 379–388. Janssen, B. (2005). 'MLPA analysis for the detection of deletions, duplications and complex rearrangements in the dystrophin gene: potential and pitfall.' Neurogenetics 6: 29–35. Nigel G Laing, M. R. D., Klair Bayley, Sue Fletcher, Steve D Wilton (2011). 'Molecular Diagnosis of Duchenne Muscular Dystrophy: Past, Present and Future in Relation to Implementing Therapies.' The Australian Association of Clinical Biochemists 32. Wei, X. (2014). 'Targeted next-generation sequencing as a comprehensive test for patients with and female carriers of DMD/BMD: a multi-population diagnostic study.' European Journal of Human Genetics 22: 110-118. Strober, J. B. (2006). 'Therapeutics in Duchenne muscular dystrophy.' The Journal of the American Society for Experimental NeuroTherapeutics 3: 225-234. Kim, S. (2014). 'Corticosteroid Treatments in Males With Duchenne Muscular Dystrophy: Treatment Duration and Time to Loss of Ambulation.' Journal of Child Neurology 30(10): 1275-1280. Dawn E Bowles, S. W. M., Chengwen Li, Steven J Gray, Jade J Samulski, Angelique S Camp, Juan Li, Bing Wang, Paul E Monahan, Joseph E Rabinowitz, Joshua C Grieger, Lakshmanan Govindasamy, Mavis Agbandje-McKenna, Xiao Xiao and R Jude Samulski (2012). 'Phase 1 Gene Therapy for Duchenne Muscular Dystrophy Using a Translational Optimized AAV Vector.' The American Society of Gene & Cell Therapy 20: 443–455. Jerry R. Mendell, M. D., Louise Rodino-Klapac, Ph.D., Zarife Sahenk, M.D., Ph.D., Vinod Malik, Ph.D., Brian K. Kaspar, Ph.D., Christopher M. Walker, Ph.D., K. Reed Clark, Ph.D. (2012). 'Gene Therapy for Muscular Dystrophy: Lessons Learned and Path Forward.' Neuroscience Letters 527(2): 90-99. Finkel, R. S. (2010). 'Readthrough Strategies for Suppression of Nonsense Mutations in Duchenne/Becker Muscular Dystrophy: Aminoglycosides and Ataluren (PTC124).' Journal of Child Neurology 25(9): 1158-1164. Bushby K, F. R., Wong B, Barohn R, Campbell C, Comi GP, Connolly AM, Day JW, Flanigan KM, Goemans N, Jones KJ, Mercuri E, Quinlivan R, Renfroe JB, Russman B, Ryan MM, Tulinius M, Voit T, Moore SA, Lee Sweeney H, Abresch RT, Coleman KL, Eagle M, Florence J, Gappmaier E, Glanzman AM, Henricson E, Barth J, Elfring GL, Reha A, Spiegel RJ, O'donnell MW, Peltz SW, Mcdonald CM; PTC124-GD-007-DMD STUDY GROUP. (2014). 'Ataluren treatment of patients with nonsense mutation dystrophinopathy.' Muscle Nerve 50(4): 477-487. Taeyoung Koo, M. J. W. (2013). 'Clinical trials using antisense oligonucleotides in duchenne muscular dystrophy.' Human gene therapy 24: 479-488. Aartsma-Rus A, F. I., Verschuuren J, Ginjaar I, van Deutekom J, van Ommen GJ, den Dunnen JT. (2009). 'Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.' Human Mutation 30(3): 293-299. Aartsma-Rus A, V. D. J., Fokkema IF, Van Ommen GJ, Den Dunnen JT. (2006). 'Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule.' Muscle & Nerve 34(2): 135-144. Moat, S. J. (2013). 'Newborn bloodspot screening for Duchenne Muscular Dystrophy: 21 years experience in Wales (UK).' European Journal of Human Genetics 21: 1049–1053. Mendell, J. R. (2012). 'Evidence-based path to newborn screening for duchenne muscular dystrophy.' Annals of Neurology 71(3): 304-313. Liu, L.-L. (2014). Development of a newborn screening technique for hyper-creatine kinase-emia. National Taiwan University Hospital, National Taiwan University. Master: 76. Schouten, J. P. (2002). 'Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification.' Nucleic Acids Research 15 30(12): 57. Lalic, T. (2005). 'Deletion and duplication screening in the DMD gene using MLPA.' European Journal of Human Genetics 13: 1231–1234. MRC-Holland (2015) Product Description SALSAR MLPAR probemixes P034-B2 DMD & P035-B1 DMD. Customer-Support-Centre (2006). 'Qualitative and Quantitative Analysis in GC and GCMS.' Shimadzu Asia Pacific Pte. Ltd. Singapore. Tommy Gerdes, M. K., Thue Bryndorf (2005). 'Automatic analysis of multiplex ligation-dependent probe amplification products (exemplified by a commercial kit for prenatal aneuploidy detection).' Electrophoresis 26: 4327–4332. QIAGEN, S. P. (2010). 'Isolation of genomic DNA from dried blood spots using the QIAampR 96 DNA Blood Kit.' Eun-Hye Choi, S. K. L., Chunhwa Ihm, and Young-Hak Sohn (2014). 'Rapid DNA Extraction from Dried Blood Spots on Filter Paper: Potential Applications in Biobanking.' Osong Public Health and Research Perspectives 5(6): 351-357. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/51721 | - |
dc.description.abstract | 背景:
裘馨氏肌肉萎縮症(Duchene muscular dystrophy, DMD)或貝克氏肌肉萎縮症(Becker muscular dystrophy, BMD)導因於DMD基因的突變,是造成男性肌肉疾病病變的一種X染色體性聯遺傳隱性疾病。DMD的發生率約每3600-6000名活產男嬰中有1個,確診的個案中約60~70%可在此段基因坐落的位置Xp21.2上發現基因缺失(deletion)或擴增(duplication)。近年來藥物治療日益進步,可以延緩發病患者的症狀,然而目前新生兒篩檢方式為檢測creatine kinase(CK)數值,敏感度有待加強,此症平均診斷年齡約5歲,若能以新生兒篩檢方式在疾病早期便確認診斷,將可望更改善預後。 研究目的: 我們希望可以建立血片萃取DNA進行多重連接擴大反應技術(multiple ligation-dependent probe amplification, MLPA)的方法,以偵測DMD基因是否有缺失或擴增,作為高CK值者的第二線檢驗工具。 實驗方法: 我們首先比較全血(whole blood, WB)標準萃取DNA方式與血片(DBS)萃取出的DNA經過濾、沉澱、DNA kit column、tissue extraction kit等處理方式的檢體,進行MLPA分析後,決定何種DNA處理方式適用於本次實驗,接著進行標準值之建立,最後比對臨床受試者以傳統檢測方式與我們方式的異同,以確認本檢驗的正確性。 結果: 我們發現以血片萃取DNA後直接回溶H2O的方式所獲得的DNA,是進行MLPA最好的檢體處理方式。經檢測8名受試者血片DMD基因缺失的結果發現,4名為DMD基因缺失、1名DMD基因擴增、與3名無DMD基因缺失與擴增,皆與全血DNA進行MLPA後的結果相同,準確率達100%。 結論: 我們建立了以濾紙血片萃取DNA 藉由MLPA的方式檢測DMD基因缺失或擴增的方式,這個方式簡單快速,未來將可用於新生兒篩檢時,針對高CK值個案的第二階段的檢測。 | zh_TW |
dc.description.abstract | Background:
Duchene muscular dystrophy (DMD) or Becker muscular dystrophy (BMD) are caused by the DMD gene mutation, which is one of the X-linked myopathy that affects mostly males. The prevalence is one in 3600-6000 in male newborns. About 60~70% of these patients can find mutation in the DMD gene, that located at Xp21.2. According to the advance in pharmaceutical development, the progress of patients can be slow down. Examination of the creatine kinase (CK) is what we use in the newborn screening test nowadays; the sensitivity needed to be improved. The average diagnosis ages of DMD is 5 years old. To improve the prognosis, it can achieve by early detection of patients via newborn screening. Purpose: We hope to establish the method to detect DMD gene deletion or duplication by DNA extracted from the dried blood spot (DBS) using multiple ligation-dependent probe amplification (MLPA) as a second tier for those with high CK values. Method: We compared the MLPA result using DNA extracted from traditional method (whole blood) with DNA extracted from DBS using different methods (direct dissolve, filtration, precipitation, DNA kit column, tissue extraction kit). Then, we chose one method from this experiment to establish the standard values. Finally, we tested the clinical samples using traditional methods with our method to check the accuracy of our method. Results: We found that the best way to handle for MLPA was to dissolve DNA in H2O directly. After testing eight clinical samples, we identified four with DMD deletion, one with DMD duplication, and three with normal DMD gene dosage. The results were comparable to traditional results. The accuracy is 100%. Conclusion: We established the MLPA method to detect DMD gene deletion or duplication using DNA from DBS. This method is simple and fast. In the future, it is suitable be the second tier test for high CK in newborn screen. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T13:46:17Z (GMT). No. of bitstreams: 1 ntu-104-P02448006-1.pdf: 6847084 bytes, checksum: e072fe2b9984c7eef61e846e0c612dd5 (MD5) Previous issue date: 2015 | en |
dc.description.tableofcontents | 口試委員審定書 I
誌謝 II 中文摘要 III 英文摘要 V 第一章:研究背景 1 第一節:裘馨氏肌肉萎縮症簡介 1 第二節:DMD的分子診斷 2 第三節:DMD的治療 4 第四節:早期診斷DMD的方式 7 第五節:實驗目的 8 第二章:實驗方法 9 第一節:樣本的收集 9 第二節:方法原理 9 第三章:實驗步驟及結果 13 第一節:建立最佳DNA萃取方式 13 第二節:建立MLPA背景標準參考值 15 第三節:疑似DMD患者樣本測試 15 第四章:討論 16 第一節:全血與血片萃取DNA差異之處 16 第二節:由血片抽取DNA方法的比較 16 第三節:試驗方法干擾因素與限制 17 第四節:未來可能的應用 17 第五章:結論 18 參考文獻 32 附錄 35 | |
dc.language.iso | zh-TW | |
dc.title | 建立血片DNA用於DMD基因之測定法 | zh_TW |
dc.title | Detection of the DMD gene deletion using DNA extracted from dried blood spots | en |
dc.type | Thesis | |
dc.date.schoolyear | 104-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 簡穎秀,李妮鍾 | |
dc.subject.keyword | 裘馨氏肌肉萎縮症,肌肉失養症,濾紙血片,多重連接擴大反應技術, | zh_TW |
dc.subject.keyword | Duchene muscular dystrophy (DMD),dystrophin,dried blood spot (DBS),multiple ligation-dependent probe amplification (MLPA), | en |
dc.relation.page | 49 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2015-11-26 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 分子醫學研究所 | zh_TW |
顯示於系所單位: | 分子醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf 目前未授權公開取用 | 6.69 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。